收费全文 | 389篇 |
免费 | 18篇 |
国内免费 | 2篇 |
耳鼻咽喉 | 3篇 |
儿科学 | 3篇 |
妇产科学 | 4篇 |
基础医学 | 42篇 |
口腔科学 | 2篇 |
临床医学 | 39篇 |
内科学 | 97篇 |
皮肤病学 | 4篇 |
神经病学 | 49篇 |
特种医学 | 9篇 |
外科学 | 64篇 |
综合类 | 1篇 |
预防医学 | 53篇 |
眼科学 | 3篇 |
药学 | 22篇 |
肿瘤学 | 14篇 |
2024年 | 1篇 |
2023年 | 4篇 |
2022年 | 10篇 |
2021年 | 33篇 |
2020年 | 7篇 |
2019年 | 20篇 |
2018年 | 28篇 |
2017年 | 14篇 |
2016年 | 14篇 |
2015年 | 15篇 |
2014年 | 21篇 |
2013年 | 23篇 |
2012年 | 35篇 |
2011年 | 36篇 |
2010年 | 14篇 |
2009年 | 24篇 |
2008年 | 25篇 |
2007年 | 20篇 |
2006年 | 14篇 |
2005年 | 14篇 |
2004年 | 14篇 |
2003年 | 12篇 |
2002年 | 5篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1992年 | 1篇 |
1945年 | 1篇 |
This study aimed at reporting a head-to-head comparison between water vapor thermal therapy using the Rezūm? system and prostatic urethral lift using the Urolift? system in men with lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
Patients and methodsFrom December 2017 to November 2019, consecutive patients who underwent Rezūm? and Urolift? procedures in two urology centers have been retrospectively considered. Only patients with a prostate size less than 80 mL were included. We used the PSM method to adjust baseline differences between both groups. The co-primary endpoint included the change in International Prostate Symptom Score (IPSS) and IPSS- quality of life (QoL) from baseline to 12 months.
ResultsA total of 61 (52.1%) and 56 (47.9%) patients underwent Rezum? and Urolift? procedures, respectively. After PSM adjustment, 24 patients were included in both groups. No serious adverse events occurred (>?Clavien II) in both groups. At 12 months, higher IPSS improvement was observed in the Rezum? group (median:4 [IQR 3–5]) than in the Urolift? group (median:8 [IQR 7–12]), without statistical difference (p?=?0.08). The improvement in term of QoL at 12 m was similar (p?=?0.43). The retreatment rates were 25% (Urolift?) and 8.3% (Rezum?), p?=?0.24. Erection and ejaculatory function scores did not change significantly in either treatment group. Results in the full cohort showed that Rezum? appeared to deliver greater improvements for IPSS and IPSS-QoL (p?<?0.001 and p?=?0.006, respectively) and lower reintervention rate (p?=?0.006) than Urolift?.
ConclusionsIn this small retrospective study, our results indicate that both Rezum? and Urolift? provide a clinically significant improvement in symptoms and QoL, although some of these improvements were greater in the Rezum? arm. Future studies are needed to definitively assess which treatment would be best suited for each patient.
相似文献